Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populations

More than 75% of epithelial ovarian cancer (EOC) patients experience disease recurrence after initial treatment, highlighting our incomplete understanding of how chemoresistant populations evolve over the course of EOC progression post chemotherapy treatment. Here, we show how two paclitaxel (PTX) t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mejia Peña, Carolina, Skipper, Thomas A., Hsu, Jeffrey, Schechter, Ilexa, Ghosh, Deepraj, Dawson, Michelle R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628134/
https://www.ncbi.nlm.nih.gov/pubmed/37932310
http://dx.doi.org/10.1038/s41598-023-46055-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628134/
https://www.ncbi.nlm.nih.gov/pubmed/37932310
http://dx.doi.org/10.1038/s41598-023-46055-6

Ejemplares similares